{
    "id": 29139,
    "fullName": "ARID1A negative",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "ARID1A negative indicates a lack of the ARID1A gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 8289,
        "geneSymbol": "ARID1A",
        "terms": [
            "ARID1A",
            "B120",
            "BAF250",
            "BAF250a",
            "BM029",
            "C1orf4",
            "CSS2",
            "ELD",
            "hELD",
            "hOSA1",
            "MRD14",
            "OSA1",
            "P270",
            "SMARCF1"
        ]
    },
    "variant": "negative",
    "createDate": "12/28/2018",
    "updateDate": "12/28/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 15495,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, ENMD-2076 treatment resulted a median progression-free survival (PFS) of 4.4 months in patients with ARIDA1A-negative recurrent ovarian clear cell carcinoma and a median PFS of 3.6 months in ARID1A-positive patients, with a statistically significant difference in estimated 6-month PFS rate (0.33 vs 0.12, p=0.023) (PMID: 30108107).",
            "molecularProfile": {
                "id": 31068,
                "profileName": "ARID1A negative"
            },
            "therapy": {
                "id": 727,
                "therapyName": "ENMD-2076",
                "synonyms": null
            },
            "indication": {
                "id": 50934,
                "name": "ovarian clear cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13398,
                    "pubMedId": 30108107,
                    "title": "A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30108107"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 31068,
            "profileName": "ARID1A negative",
            "profileTreatmentApproaches": [
                {
                    "id": 19505,
                    "name": "EZH2 inhibitor",
                    "profileName": "ARID1A negative"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}